A pilot study on the association between RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort.

Statin, the first-line treatment for dyslipidaemia, may have suboptimal adherence due to its associated muscle adverse events. These data, however, remain limited. To determine the association of serum creatine kinase (CK) and rs4363657 polymorphism with statin-associated muscle adverse events (SAMAE) among dyslipidaemia participants. This was a prospective cohort study at government health clinics involving newly diagnosed adults with dyslipidaemia. SAMAE were recorded based on the patient's complaint after a month on statin. CK was taken at baseline and follow-up. Genetic profiling was performed for rs4363657 polymorphism. Among 118 participants, majority were Malay (72%) males (61%) with a mean age of 49 ± 12.2 years old and prescribed lovastatin (61.9). There was a significant association between statin types (lovastatin and simvastatin) and SAMAE ( = 0.0327); no significant association noted between CK and SAMAE ( = 0.5637). The rs4363657 polymorphism was significantly associated SAMAE ( < 0.0001). In this first pilot study of a multiethnic Malaysian population, the incidence of SAMAE was 18.6%. SAMAE were significantly higher in subjects on lovastatin compared to simvastatin. rs4363657 polymorphism was a significant risk factor for SAMAE.